Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
DAWN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.41 - $17.14
Previous CloseN/A
Volume175.11K
Average Volume (3M)1.09M
Market Cap
$708.46M
Enterprise Value$752.02M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 12, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding101,353,780
10 Day Avg. Volume1,039,782
30 Day Avg. Volume1,089,953
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.48
Forecast
1Y Price Target
$31.67Price Target Upside402.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Day One Biopharmaceuticals News
See All DAWN News
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDay One Biopharmaceuticals reported a robust cash position of $473 million, a best-in-class commercial product, an experienced management team, and is currently at its lowest valuation in over 30 months, presenting a buying opportunity with a holding period of at least 12 months.
Market ExpansionThe potential for development outside the US (with the EMA accepting regulatory filing for review in April 2025) may offer another avenue for the topline in 2026+.
Product GrowthOjemda sales continued to demonstrate growth based on new patient adds, high percentage of on-patients continuing on therapy, and increased treatment duration.
Bears Say
Adoption Rate ConcernsPressure on the stock is from concerns around the adoption rate in 2025, as management mentioned that the sales ramp would be similar to a rare disease drug due to infrequency of treatment decisions.
Patient DiscontinuationsRoughly 30-40% of discontinuations were in patients receiving Ojemda via off-label use or in those with fast-progressing disease.
Prescription TrendsOjemda TRx trends were slightly below expectations.
---
Ownership Overview
17.59% Insiders
22.14% Mutual Funds
0.21% Other Institutional Investors
48.95% Public Companies and
Individual Investors
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $6.41 and its highest was $17.14 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Day One Biopharmaceuticals’s market cap is $708.46M.
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is Aug 12, 2025 which is in 95 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on May 06, 2025. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.438 by $0.088.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -0.35.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 101,353,780 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.438. Following the earnings report the stock price went down -9.871%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Currently, no hedge funds are holding shares in DAWN
---
Day One Biopharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.67 (402.70% Upside)
$31.67 (402.70% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 7.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.89%
12-Months-Change
Fundamentals
Return on Equity
-17.80%
Trailing 12-Months
Asset Growth
54.98%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
---
DAWN Company Deck
---
DAWN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased strong revenue growth for OJEMDA, a robust financial position, and progress in clinical trials and regulatory processes, despite some seasonal challenges and high operating expenses.Read More>---
DAWN Stock 12 Month Forecast
Average Price Target
$31.67
▲(402.70% Upside)
Technical Analysis
Anavex Life Sciences
―
Zymeworks
―
Xeris Pharmaceuticals
―
Nurix Therapeutics
―
Pharvaris
―
---